NCT06375109 (NeoSCLC-001) is a Phase 2 clinical trial of Tislelizumab in Limited-stage Small-cell Lung Cancer, sponsored by Beijing Chest Hospital, Capital Medical University.

Who is sponsoring NCT06375109?

NCT06375109 is sponsored by Beijing Chest Hospital, Capital Medical University.

What drugs are being tested in NCT06375109?

Interventions in NCT06375109: Tislelizumab, Carboplatin injection, Cisplatin injection, Etoposide injection.

What condition does NCT06375109 study?

NCT06375109 studies Limited-stage Small-cell Lung Cancer.

Is NCT06375109 still recruiting?

NCT06375109 is currently not yet recruiting. Last updated 19 April 2024.

Last reviewed 2024-04-19 · How we verify

NCT06375109: NeoSCLC-001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

Not yet recruiting Phase 2 Last updated 19 April 2024

What this trial tests

Phase 2 trial testing Tislelizumab in Limited-stage Small-cell Lung Cancer in 60 participants. Not yet recruiting.

Timeline

16 April 2024

Primary endpoint
15 April 2027

15 April 2029

Quick facts

Lead sponsor	Beijing Chest Hospital, Capital Medical University
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	16 April 2024
Primary completion	15 April 2027
Estimated completion	15 April 2029

Drugs / interventions tested

Tislelizumab (TISLELIZUMAB) — full drug profile →
Carboplatin injection — full drug profile →
Cisplatin injection — full drug profile →
Etoposide injection

Conditions studied

Limited-stage Small-cell Lung Cancer — all drugs for Limited-stage Small-cell Lung Cancer →

Sponsor

Beijing Chest Hospital, Capital Medical University

Who can join

Adults 18 to 75, any sex, with Limited-stage Small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, non-randomized, controlled, single-center, phase II study to compare the efficacy and safety of neoadjuvant PD-L1/PD-1 inhibitor + chemotherapy (carboplatin/cisplatin + etoposide) with chemotherapy (carboplatin/cisplatin + etoposide) alone followed by radical surgery and adjuvant treatment as perioperative therapy in patients with limited-stage SCLC.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and safety of neoadjuvant chemotherapy with or without PD-L1/PD-1 inhibitors in surgically limited-stage small-cell lung cancer.
Shi L, Li H, Guo L, Tang J, et al · · 2025 · PMID 41132956 · DOI 10.21037/tlcr-2025-438

Verify or expand the search:

Other trials of Tislelizumab

Trials testing the same drug.

NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting

Other recruiting trials for Limited-stage Small-cell Lung Cancer

Currently open trials in the same condition.

NCT07242547 — Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients · Phase 2 · recruiting

Other Beijing Chest Hospital, Capital Medical University trials

Trials by the same sponsor.

NCT06467617 — Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06375109 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Chest Hospital, Capital Medical University
Last refreshed: 19 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06375109.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing